Drug Development
The shift in Glaxo’s R&D structure was also evi-
denced by its creation of Centres of Excellence for Drug Discovery (CEDDs), each focused on a differ- ent research track. The company subsequently went on to establish a Centre of Excellence for External Drug Development (CEEDD), sharing some of its assets for development by others when more potential targets were generated than GSK had the internal resource to develop. Where big pharma led, others followed and,
alongside academic collaborations, a proliferation in the number of biotechs in the last decade has seen an increase in partnerships across the board and an array of licensing arrangements for new assets. As a network of independent associated compa-
nies operating across 120 countries worldwide, Mundipharma was founded on a partnership working model. Entrepreneurial at its heart, Mundipharma has always sought out opportuni- ties for long-term relationships with independent companies to foster innovation, meet the chal- lenges of increasingly stretched healthcare systems and increase patient access to effective therapies. In short, we exist to meet our stated purpose: To Move Medicine Forward. Sometimes this involves focusing on innovation
by acquiring compounds with interesting new mechanisms of action and fast-tracking them to the point of investigational new drug (IND) status.
Drug Discovery World Winter 2019/20
This is the case with one of our oncology assets which is now entering Phase I research for the treatment of relapsed/refractory haematological malignancies and Phase II for the treatment of advanced solid tumours. At other times we might acquire something further along the clinical devel- opment pathway and use our specialist R&D knowledge in a disease area to identify the right indication or specific patient population. Mundipharma partners with organisations that
have already achieved marketing authorisation for their medicines in some markets but are looking to expand their reach with the support of our in- depth local knowledge and relationships. We have found the key is to be strategic in our
choices, looking for the opportunities that others may miss.
Partnering to treat and prevent invasive fungal infections – a case study A good example of the Mundipharma partnership approach in action is in the case of rezafungin, a novel molecule in the echinocandin class of anti- fungals, developed by Cidara Therapeutics – a clin- ical-stage biotechnology company focused on the discovery, development and commercialisation of novel anti-infectives. Invasive fungal infections (IFIs) represent a seri- ous threat to millions of patients worldwide,
53
Rezafungin is a novel, once-weekly echinocandin antifungal being developed for the first-line treatment of candidemia and invasive candidiasis as well as for the prophylaxis of invasive fungal infections in patients undergoing allogeneic blood and marrow transplantation
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
